PMEL and melanoma: In patients treated with ipilimumab and gp100, in which the response rate and OS data were similar to those observed in ipilimumab alone arm, the median duration of response was, however, 11.5 months.26 Other very promising immunomodulating agent – pembrolizumab (Keytruda, Merck, Kenilworth, NJ) (anti-PD1) was recently approved by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.